Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.88 |
| ▸ | MAPT | P10636 | 4/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.88 |
| ▸ | NPC1 | O15118 | 3/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.88 |
| ▸ | AHR | P35869 | 1/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | USP8 | P40818 | 2/20 | 0.53 |
| ▸ | USP7 | Q93009 | 1/20 | 0.53 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 3/20 | 0.50 |
| ▸ | APAF1 | O14727 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824427 | 0.93 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL15196680 | 0.84 | MAPT (0.67) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2489961 | 0.83 | MAPT (0.73) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17333584 | 0.81 | MAPT (0.70) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2681287 | 0.79 | RAB9A (0.74) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL25879765 | 0.79 | RAB9A (0.57) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19304794 | 0.79 | RAB9A (0.91) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| Anthraquinone SCHEMBL5550279 | 0.79 | MAPT (0.67) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL15196935 | 0.79 | MAPT (0.67) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL18462381 | 0.78 | RAB9A (0.93) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051345-B2 | Metalloinsertor complexes targeted to DNA mismatches | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014200497-A1 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8859533-B2 | Metalloinsertor complexes targeted to DNA mismatches | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8825411-B2 | Design, synthesis and assembly of synthetic nucleic acids | DNA TWOPOINTO, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2441769-B1 | Design, synthesis and assembly of synthetic nucleic acids | REPLIGEN CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2707377-A2 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | California Institute of Technology (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130345189-A1 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-12-26 | — | — | US | disclosed |
| US-20130196864-A1 | DESIGN, SYNTHESIS AND ASSEMBLY OF SYNTHETIC NUCLEIC ACIDS | DNA TWOPOINTO, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130090319-A1 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2013-04-11 | — | — | US | disclosed |
| WO-2012155004-A2 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | CALIFORNIA INSITUTE OF TECHNOLOGY (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2441769-A1 | Design, synthesis and assembly of synthetic nucleic acids | REPLIGEN CORPORATION (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100093611-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | AVALON PHARMACEUTICALS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093611-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | AVALON PHARMACEUTICALS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20090317873-A1 | Design, synthesis and assembly of synthetic nucleic acids | DNA TWOPOINTO, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20080300842-A1 | Design, Synthesis and Assembly of Synthetic Nucleic Acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2008144011-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | AVALON PHARMACEUTICALS (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7345172-B2 | Methods and compositions for detecting polynucleotide duplex damage and errors | CALFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1771579-A2 | DESIGN, SYNTHESIS AND ASSEMBLY OF SYNTHETIC NUCLEIC ACIDS | DNA TWOPOINTO INC. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005115102-A2 | DESIGN, SYNTHESIS AND ASSEMBLY OF SYNTHETIC NUCLEIC ACIDS | DNA TWOPOINTO, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093611-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | IKBKB, IKBKG, NFKBIA | RAB9A 2834/4885MAPT 3345/4885SMN1; SMN2 4218/4885 |
| US-20130090319-A1 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | MSH2, MSH6, PMS2 | RAB9A 1218/4885MAPT 3901/4885SMN1; SMN2 1023/4885 |
| US-20130345189-A1 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES | MSH2, MSH6, PMS2 | RAB9A 1218/4885MAPT 3901/4885SMN1; SMN2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.